$ #novo nordisk novos diabetes drugs face u.s. price pressure, but new launches support a wide moat.: novo nordisk released results for 2017 that were slightly disappointing on the top line but relatively in line with our eps projections, and guidance… https://t.co/snhyeqkdfh https://t.co/wzk21lllgs